Compare Cassava Sciences Inc (FLNA) vs Philip Morris International Inc. (PM) Price & Performance

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Philip Morris International (PM) trades at $186.22, down 1.77% with mixed technical signals. The company reported strong Q1 and Q2 2026 earnings beats but faces margin pressure from rising costs. Revenue grew to $40.65B in 2025 with a robust 25.56% net income margin. Analyst consensus remains bullish with a $211.17 price target, though recent news highlights challenges including a $500M impairment charge and increased illicit cigarette trade in Europe.

PM offers solid fundamentals with high profitability and dividend yield, but near-term headwinds from cost inflation and regulatory risks warrant caution. The stock's valuation at 25.54x P/E is reasonable given earnings growth potential, making it attractive for long-term investors despite current volatility.